97 related articles for article (PubMed ID: 20815986)
21. [Anti-survivin and anti-livin antibodies].
Yagihashi A
Nihon Rinsho; 2010 Jun; 68 Suppl 6():708-10. PubMed ID: 20942170
[No Abstract] [Full Text] [Related]
22. [The estimation of serum concentration of vascular endothelial growth factor in patients with non-small cell lung cancer].
Kopczyńska E; Dancewicz M; Kowalewski J; Kardymowicz H; Tyrakowski T
Pol Merkur Lekarski; 2007 Jun; 22(132):536-8. PubMed ID: 17874624
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the relationship between serum carcinoembryonic antigen level and treatment outcome in surgically resected clinical-stage I patients with non-small-cell lung cancer.
Hotta K; Segawa Y; Takigawa N; Kishino D; Saeki H; Nakata M; Mandai K; Eguchi K
Anticancer Res; 2000; 20(3B):2177-80. PubMed ID: 10928173
[TBL] [Abstract][Full Text] [Related]
24. Expression of CD44v6 and Livin in gastric cancer tissue.
Liang YZ; Fang TY; Xu HG; Zhuo ZQ
Chin Med J (Engl); 2012 Sep; 125(17):3161-5. PubMed ID: 22932199
[TBL] [Abstract][Full Text] [Related]
25. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
Li R; Li R; Wang Y
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
[TBL] [Abstract][Full Text] [Related]
26. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
[TBL] [Abstract][Full Text] [Related]
27. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
[TBL] [Abstract][Full Text] [Related]
28. [Expression of apoptosis inhibitor gene Livin in bladder transitional cell carcinoma and clinical implication thereof].
Song T; Hong BF; Gao JP; Cai W; Wang CY
Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(12):806-7. PubMed ID: 17565859
[TBL] [Abstract][Full Text] [Related]
29. [Expression of apoptosis inhibitor gene Livin in prostate cancer and its clinical implication].
Song T; Hong BF; Gao JP; Zhang L; Cai W
Zhonghua Nan Ke Xue; 2008 Jan; 14(1):30-3. PubMed ID: 18297808
[TBL] [Abstract][Full Text] [Related]
30. Prognostic markers for stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N
Lung Cancer; 2008 Feb; 59(2):274-5. PubMed ID: 18055061
[No Abstract] [Full Text] [Related]
31. Persistently high serum carcinoembryonic antigen levels after surgery indicate poor prognosis in patients with stage I non-small-cell lung cancer.
Wang CY; Huang MS; Huang MH; Lee HC; Hsu HS
J Surg Res; 2010 Oct; 163(2):e45-50. PubMed ID: 20638687
[TBL] [Abstract][Full Text] [Related]
32. The importance of alpha-1 antitrypsin (alpha1-AT) and neopterin serum levels in the evaluation of non-small cell lung and prostate cancer patients.
El-Akawi ZJ; Abu-Awad AM; Sharara AM; Khader Y
Neuro Endocrinol Lett; 2010; 31(1):113-6. PubMed ID: 20150872
[TBL] [Abstract][Full Text] [Related]
33. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
34. Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery.
Dai CH; Li J; Shi SB; Yu LC; Ge LP; Chen P
Jpn J Clin Oncol; 2010 Apr; 40(4):327-35. PubMed ID: 20056675
[TBL] [Abstract][Full Text] [Related]
35. Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer.
Park JH; Choi H; Kim YB; Kim YS; Sheen SS; Choi JH; Lee HL; Lee KS; Chung WY; Lee S; Park KJ; Hwang SC; Lee KB; Park KJ
Lung Cancer; 2009 Dec; 66(3):359-64. PubMed ID: 19339077
[TBL] [Abstract][Full Text] [Related]
36. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
37. Serum endostatin levels in patients with lung carcinoma.
Swidzińska E; Ossolińska M; Naumnik W; Trojan S; Chyczewska E
Rocz Akad Med Bialymst; 2005; 50():197-200. PubMed ID: 16358965
[TBL] [Abstract][Full Text] [Related]
38. Circulating apoptotic markers in the management of non-small cell lung cancer.
Holdenrieder S; Stieber P
Cancer Biomark; 2010; 6(3-4):197-210. PubMed ID: 20660965
[TBL] [Abstract][Full Text] [Related]
39. Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer.
Hofmann HS; Simm A; Hammer A; Silber RE; Bartling B
J Cancer Res Clin Oncol; 2002 Oct; 128(10):554-60. PubMed ID: 12384799
[TBL] [Abstract][Full Text] [Related]
40. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma.
Gordon GJ; Mani M; Mukhopadhyay L; Dong L; Edenfield HR; Glickman JN; Yeap BY; Sugarbaker DJ; Bueno R
J Pathol; 2007 Mar; 211(4):447-54. PubMed ID: 17253596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
